Insidon

Opipramol Hydrochloride, the active ingredient in Insidon, is a tricyclic antidepressant/anxiolytic presented as an oral tablet for oral use. It is employed in the management of generalized anxiety disorder, other anxiety disorders, and depressive disorders in adult patients. It is indicated for adult patients and is available in the European market under prescription.

GNH USA supplies Insidon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Opipramol Hydrochloride is used to treat anxiety and depressive disorders.

- Generalized anxiety disorder: reduces anxiety symptoms and improves overall functioning. - Other anxiety disorders: alleviates excessive worry and tension associated with various anxiety conditions. - Depressive disorders: helps improve mood and alleviates depressive symptoms in adult patients.

Opipramol Hydrochloride may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Dry mouth: decreased salivation leading to oral discomfort. - Dizziness: sensation of light‑headedness or imbalance. - Constipation: reduced bowel movements or difficulty passing stool. - Blurred vision: temporary visual disturbances. - Weight gain: increase in body weight over time.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm that may require medical attention. - Severe hypotension: marked drop in blood pressure causing faintness. - Seizures: convulsive episodes that need urgent care. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Liver enzyme elevation: signs of hepatic stress detectable in lab tests. - Suicidal thoughts: emergence of suicidal ideation requiring immediate evaluation.

When prescribing Opipramol Hydrochloride, clinicians should consider several safety measures.

- Assess hepatic function: evaluate liver enzymes before initiating therapy. - Monitor for sedation: advise patients about reduced alertness and operating machinery. - Avoid abrupt discontinuation: taper the dose under medical supervision to prevent withdrawal. - Use caution in elderly: increased sensitivity to anticholinergic and sedative effects. - Pregnancy and lactation: safety not established; use only if potential benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Opipramol Hydrochloride can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may cause severe hypertensive reactions. - CNS depressants: combined effect can enhance sedation and respiratory depression. - Alcohol: may intensify drowsiness and impair coordination.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors: may increase risk of serotonin syndrome. - CYP450 inhibitors: can raise Opipramol plasma levels, requiring dose adjustment.